Adaptive Biotechnologies (ADPT) exec trades shares under Rule 10b5-1 plan

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an option exercise and related share sale. On April 27, 2026, she completed an open-market sale of 19,037 shares of common stock at a weighted average price of $14.23 per share.

That same day, she exercised stock options to acquire 14,707 shares of common stock at an exercise price of $8.46 per share from a grant vesting over four years and expiring in 2033. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 19,037 shares ($270,897)

Net Sell 3 txns

Insider RUBINSTEIN JULIE

Role President and COO

Sold 19,037 shs ($271K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	14,707	$0.00	--
Exercise	Common Stock	14,707	$8.46	$124K
Sale	Common Stock	19,037	$14.23	$271K

Holdings After Transaction: Stock Option (right to buy) — 45,731 shares (Direct, null); Common Stock — 396,839 shares (Direct, null)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Key Figures

Shares sold: 19,037 shares Sale price: $14.23 per share Options exercised: 14,707 shares +2 more

5 metrics

Shares sold 19,037 shares Common stock sold in open-market transaction on April 27, 2026

Sale price $14.23 per share Weighted average sale price; trades ranged from $14.08 to $14.34

Options exercised 14,707 shares Common stock acquired via option exercise on April 27, 2026

Option exercise price $8.46 per share Exercise price for stock options converted into common shares

Remaining options 45,731 options Stock Option (right to buy) position after transactions; expires March 6, 2033

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported for this transaction is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

vesting financial

"The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

04/29/2026 - 07:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/27/2026		M⁽¹⁾		14,707	A	$8.46	396,839	D
Common Stock	04/27/2026		S⁽¹⁾		19,037	D	$14.23⁽²⁾	377,802	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$8.46	04/27/2026		M⁽¹⁾			14,707	⁽³⁾	03/06/2033	Common Stock	14,707	$0	45,731	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider stock transactions did Julie Rubinstein report at Adaptive Biotechnologies (ADPT)?

Julie Rubinstein reported both an option exercise and a share sale. She exercised options for 14,707 shares of common stock and sold 19,037 shares in an open-market transaction, all dated April 27, 2026, according to the Form 4 filing.

How many Adaptive Biotechnologies (ADPT) shares did Julie Rubinstein sell and at what price?

She sold 19,037 shares of Adaptive Biotechnologies common stock. The filing reports a weighted average sale price of $14.23 per share, with individual trades executed between $14.08 and $14.34 on April 27, 2026, as described in the transaction footnotes.

What stock options did Julie Rubinstein exercise in this Adaptive Biotechnologies (ADPT) Form 4?

She exercised options covering 14,707 shares of common stock. These options had an exercise price of $8.46 per share, vested over four years starting March 4, 2024, and are part of a grant scheduled to expire on March 6, 2033.

Were Julie Rubinstein’s ADPT trades made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 plan. A footnote explains they were effected pursuant to a trading plan adopted on November 18, 2025, indicating the timing of these trades was pre-arranged rather than decided spontaneously.

What vesting terms apply to the Adaptive Biotechnologies stock options exercised by Julie Rubinstein?

The options vest over four years with monthly installments. One quarter of the shares vested on March 4, 2024, and one forty-eighth of the shares vests at the end of each full month of continuous service thereafter until the grant is fully vested.

How many Adaptive Biotechnologies stock options remain from this grant after the reported exercise?

The filing shows 45,731 stock options remaining from this grant. These are described as “Stock Option (right to buy)” with an exercise price of $8.46 per share and an expiration date of March 6, 2033, following the 14,707-share exercise.